TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01140087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Face Transplant
Description: Transplantation of donor facial skin, tissue, muscle, and bone as needed
Study: NCT03987945

Intervention type: DEVICE
Intervention: left atrial appendage occlusion devices
Description: All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
Study: NCT01665937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
Study: NCT02412865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit4Baby

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text4Baby
Study: NCT03012776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Posterior Spine System (TOPS)
Description: Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Lumbar Interbody Fusion (TLIF)
Description: Fusion with placement of interbody cage and posterolateral instrumentation
Study: NCT01873144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1/1000
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1/1000
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSS 3%
Description: Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS (0.9%)
Description: Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
Study: NCT02412865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4Baby
Study: NCT02876978

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day x 2 days
Study: NCT02136589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dicrofenac and travoprost
Description: dicrofenac drop 3 times a day travoprost 0.005% once daily
Study: NCT01240694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-33457
Description: CEP-33457 will be administered subcutaneously per dose specified in the arm description.
Study: NCT02590783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental intervention surgery
Description: Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control intervention
Description: Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
Study: NCT02689778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
Study: NCT01613976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study: NCT00481507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
Study: NCT02420782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6282
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Pilocarpine
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral
Study: NCT02618356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed and S-1
Description: Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d
Study: NCT01789931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifebeam
Description: The lifebeam sensor will be attached to the participant's skin during the HTT.
Study: NCT01030601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: 0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
Study: NCT01059929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
Study: NCT02689778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets without active substance
Study: NCT05190133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201602 and co-administration of UIC201601 and UIC201602
Description: * UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UIC201601 and co-administration of UIC201601 and UIC201602
Description: * UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days
Study: NCT00042978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV
Study: NCT03591419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polymer clip
Description: polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoloop
Description: endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
Study: NCT06228989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restorative therapy
Description: Restorative treatment of first permanent molars affected with severe MIH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restorative therapy
Description: Restorative treatment of first permanent molars affected with severe MIH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction therapy
Description: Extraction treatment of first permanent molars affected with severe MIH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction therapy
Description: Extraction treatment of first permanent molars affected with severe MIH
Study: NCT04256200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest 2 MG Oral Tablet
Description: Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: 0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
Study: NCT04820504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Infant Resuscitator (AIR)
Description: Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AIR device without feedback
Description: Device provides no visual feedback to clinician but records data on ventilation effectiveness
Study: NCT00580281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test, urine test, and bone density x-ray.
Description: start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
Study: NCT04383678

Intervention type: DEVICE
Intervention: Extracorporeal membrane oxygenation
Description: Veno-venous or veno-arterial extracorporeal oxygenation
Study: NCT02641821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Study: NCT03644888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance program
Description: Already in arm/group descriptions
Study: NCT01848275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool®Rcatheter
Description: The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
Study: NCT03027934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor, 90mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor, 90mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasurgrel, 10mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasurgrel, 10mg once daily
Study: NCT01848275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool®Rcatheter
Description: The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
Study: NCT03644888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance program
Description: Already in arm/group descriptions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Airway clearance program
Description: Already in arm/group descriptions
Study: NCT00485303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
Study: NCT01785316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IHP
Study: NCT00147238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10 (USPIO)
Description: Intravenous infusion of 2.6 mg/kg of ferumoxtran-10

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR lymphangiography
Description: First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR lymphangiography
Description: First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
Study: NCT00102973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLK286 in Combination with Carboplatin
Description: Experimental Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin HCl Liposome Injection
Description: Active Comparator
Study: NCT01970371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Study: NCT03644888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration therapy
Description: Already in arm/group descriptions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibration therapy
Description: Already in arm/group descriptions
Study: NCT03108911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard diet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Provide stool sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Provide stool sample
Study: NCT03793543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Study: NCT01970371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Study: NCT00590161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline (PTX)
Description: 400 mg PO tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tid
Study: NCT05602428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine sub-anesthetic,
Description: the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine sub-anesthetic
Description: Esketamine subanesthetic dose combined with lumbar plexus block was used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine sub-anesthetic
Description: general anesthesia was performed with esketamine subanesthetic dose.
Study: NCT01970371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Study: NCT03108911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive GFD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01069536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide 10 mg
Study: NCT00808171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livopan
Description: Inhalation of oxygen and nitrous oxide 50%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livopan
Description: equimolar mixture of N2O/O2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: Lidocaine-prilocain cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: Lidocaine-prilocain cream
Study: NCT04396015

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bulletproof Brain Octane
Description: Medium chain triglyceride oil (MCT)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bulletproof Brain Octane
Description: Medium chain triglyceride oil (MCT)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (olive) oil
Study: NCT02384876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.
Study: NCT02216006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, conventional ventilatory settings
Description: Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High fresh gas flow, high minute ventilation
Description: Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Study: NCT05277779

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance(CMR)
Description: CMR was performed to assess myocardial tissue characteristics in the study population

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance(CMR)
Description: CMR was performed to assess myocardial tissue characteristics in the study population

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance(CMR)
Description: CMR was performed to assess myocardial tissue characteristics in the study population
Study: NCT02135263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10 mg as a single dose followed by blood samples for the next 33 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 10 mg as a single dose followed by blood samples for the next 72 hours
Study: NCT05088343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: 7.5 mg hetrombopag was administered on Day 6 to Day 11.
Study: NCT03422653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.5 mcg/kg
Description: IV medication delivered three times/week
Study: NCT01970371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic of Investigator's choice